MENACTRA

Diphtheria Toxoid Conjugate VaccineMenactra is a vaccine designed to protect against meningococcal disease, a serious bacterial infection caused by Neisseria meningitidis. This infection can lead to meningitis, an inflammation of the protective membranes covering the brain and spinal cord, as well as septicemia, a life-threatening bloodstream infection. Meningococcal disease can progress rapidly and is potentially fatal, making vaccination crucial, especially for those at higher risk.Menactra ®, Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine

How It Works

Menactra is a conjugate vaccine that targets four of the most common serogroups of Neisseria meningitidis—A, C, W, and Y. The vaccine contains inactivated bacterial polysaccharides linked to a protein, which helps the immune system recognize and fight off the bacteria if exposed. By stimulating the production of antibodies, Menactra provides immunity against these specific strains.

Administration

• Dosage: Menactra is typically administered as a single dose.
• Schedule:
  • Primary Vaccination:

• Children 9 through 23 months of age: Two doses, three months apart.

• Individuals 2 through 55 years of age: A single dose.

• Booster Vaccination:
• • A single booster dose may be given to individuals 15 through 55 years of age at

continued risk for meningococcal disease, if at least 4 years have elapsed since the prior dose.

• Administration Method: Given as an intramuscular injection, usually in the upper arm (deltoid muscle).

Side Effects

Common side effects may include:

• Pain or swelling at the injection site
• Redness or tenderness at the injection site
• Headache
• Fatigue
• Mild fever

Severe reactions are rare.

Pregnancy and Lactation

• Pregnancy: Menactra can be administered during pregnancy if there is a significant risk of exposure to meningococcal disease. It is advisable to consult with a healthcare provider.
• Lactation: Safe for breastfeeding mothers.

Age Group

• Minimum Age: Approved for use in individuals starting at 9 months old.
• Upper Age Limit: Generally administered up to 55 years old, though it can be given to older adults in certain circumstances.

Contraindications

• Allergic Reactions: Not recommended for individuals with severe allergies to any component of the vaccine or to a previous dose of a meningococcal vaccine.
• Severe Illness: Vaccination should be postponed in cases of acute, severe febrile illness, previous GBS

Nature of Antigen

• Nature of Antigen: Menactra contains inactivated bacterial polysaccharides from Neisseria meningitidis serogroups A, C, W, and Y, conjugated to a protein carrier.

Vaccine Type

• Type: Menactra is a quadrivalent conjugate vaccine, meaning it protects against four different serogroups (A, C, W, Y) of the meningococcal bacteria.

Origin and Manufacturer

• Origin: Menactra is an imported vaccine.
• Manufacturer: The vaccine is produced by Sanofi Pasteur, a global vaccine manufacturer.
• Introduction Year: Menactra was introduced in 2005.

Menactra is a key vaccine for preventing meningococcal disease, particularly for adolescents, college students, military personnel, and travelers to regions where the disease is common. Developed and produced by Sanofi Pasteur, Menactra provides effective protection against four major strains of meningococcal bacteria. Always consult healthcare providers for detailed vaccination schedules and personalized advice.